Loading
Tvardi Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$16.6M
Tvardi Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Tvardi Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. Nothing new has been filed by managers of Tvardi Therapeutics, Inc. in twelve months, the latest record being from 5 August 2025.
Looking back to 2016, when coverage begins, insiders filed no purchases and 63 sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
108
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€2M
63 ops. · all time
Who traded when
BuySaleChristopher Posner3 sales
Scott Terrillion1 sale
Analyst consensus: bullish or bearish?
Analysts rate Tvardi Therapeutics, Inc. Buy (bullish), based on 8 analysts. Average price target: US$8.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.77
Analyst consensus
8 analystsBuy
US$3.00Target US$8.50(+382%)US$13.00
Income statement
RevenueUS$6.1M
EBITDA-US$26.7M-434% margin
Net income-US$18.2M0.0% margin
Valuation
PER (forward)-0.6x
P/Book1.1x
Balance sheet & cash
Market capUS$16.6M
Total debtUS$201k
Free Cash Flow-US$23.5M
Debt / Equity1%
Profitability & ownership
ROA-68.6%
% insiders26.0%
% institutions19.6%
Last declaration on 5 August 2025
Declarations108 total
315,658 shares0Common StockSEC:0001415889-25-021100:0
44,712 sharesCommon StockSEC:0001415889-25-011859:0
176,030 sharesCommon StockSEC:0001415889-25-011857:0
4,191 sharesCommon StockSEC:0001415889-25-010980:0
44,712 sharesCommon StockSEC:0001415889-25-010984:0
163 shares@ US$4.760.4% of flowCommon StockSEC:0001415889-25-006575:0
583 shares@ US$4.750.8% of flowCommon StockSEC:0001415889-25-006576:0
372 shares@ US$4.720.5% of flowCommon StockSEC:0001415889-25-003295:0
3,668 shares@ US$0.290.3% of flowCommon StockSEC:0001415889-24-026248:0
4,149 shares@ US$0.350.4% of flowCommon StockSEC:0001415889-24-020605:0
150,647 shares0Common StockSEC:0001415889-24-015756:0
150,647 shares0Common StockSEC:0001415889-24-015765:0
150,647 shares0Common StockSEC:0001415889-24-015760:0
301,295 shares0Common StockSEC:0001415889-24-015751:0
150,647 shares0Common StockSEC:0001415889-24-015763:0
3,936 shares@ US$0.750.8% of flowCommon StockSEC:0001415889-24-012322:0
2,753 shares@ US$0.831.3% of flowCommon StockSEC:0001415889-24-010569:0
2,753 shares@ US$0.830.8% of flowCommon StockSEC:0001415889-24-010570:0
5,834 shares@ US$0.891.4% of flowCommon StockSEC:0001415889-24-006273:0
3,293 shares@ US$0.891.6% of flowCommon StockSEC:0001415889-24-006282:0
3,293 shares@ US$0.891.1% of flowCommon StockSEC:0001415889-24-006265:0
7,770 shares@ US$0.531.2% of flowCommon StockSEC:0001415889-24-003400:0
35,575 shares@ US$0.535.1% of flowCommon StockSEC:0001415889-24-003395:0
5,488 shares@ US$0.53100.0% of flowCommon StockSEC:0001415889-24-003404:0
7,770 shares@ US$0.532.0% of flowCommon StockSEC:0001415889-24-003408:0
25 of 108 declarations
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It specializes in the discovery and commercialization of targeted therapies.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
